UNSPSC 51372033: Morphine methylbromide

This classification denotes an opiate C18H22NO3.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1A51P5NGGU, chemically known as morphinanium, 7,8-didehydro-4,5-epoxy-3,6-dihydroxy-17,17-dimethyl-, bromide, (5.alpha.,6.alpha.)-, but more generally known as morphine methylbromide, which bears US NIH Compound Identifier 5362445. Most nations, for tariff and trade purposes, schedule morphine methylbromide under HS 29391100 and SITC 54141. As of Q4 2014, MORPHINE METHYLBROMIDE remains US FDA's Preferred Term for this commodity.

SMILES: C[N+]1(CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O)C.[BR-].

UNSPSC 51372033 Morphine methylbromide is a Commodity code that in practice encompasses pharmaceutical procurement by state and local health agencies, including naloxone, generic multi-source drugs, and over-the-counter products acquired through competitive bidding and cooperative purchasing arrangements. State and local buyers under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The scope of work reflects acquisition of finished pharmaceutical products for community health initiatives, emergency response programs, and broader pharmacy benefit programs rather than raw chemical inputs; recent solicitations show demand for naloxone kits and drug deactivation systems for harm-reduction initiatives, generic pharmaceuticals distributed through authorized wholesalers to state and local facilities, and direct-to-manufacturer prescription fulfillment capacity serving self-insured employee health plans and government agencies.

Activity under the code centers on Florida, Texas, and Minnesota, with multistate reach through cooperative vehicles like MMCAP. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (response deadline July 26, 2023), the Texas Health and Human Services Commission's RFI HHS0017013 on direct-to-manufacturer prescription programs posted April 3, 2026, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with proposals due March 26, 2026. Successful vendors typically must maintain FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, established relationships with pharmaceutical wholesalers, and substantial insurance coverage including commercial general liability; contracts often include two-year initial terms with renewal options and are structured around fixed pricing, net-price models, or WAC-minus arrangements depending on the procuring body's requirements.